Sellas Life Sciences: A 639% Run-Up Hangs on a Milestone the Company Hasn't Confirmed

Sellas stock surges on speculation of Phase 3 AML trial hitting 80 events, but company silence and binary risk keep analysts split.

The arithmetic is almost absurd on its face. Twelve months ago, Sellas Life Sciences traded at €1.22. Today, the stock changes hands near €12.75, a gain of roughly 898 percent from that November trough. Even after a 6.5 percent pullback on Tuesday — which left the shares at €12.20 before Wednesday's 4.5 percent rebound to €12.75 — the twelve-month advance stands at 639 percent. For a biotech with a market value that would barely register among the sector's large caps, the move has been nothing short of extraordinary.

What's driving it? A single, unconfirmed number: 80.

That's the event count that triggers the final analysis of REGAL, the Phase 3 trial of galinpepimut-S in acute myeloid leukemia. A report circulating in the market claims the study has reached that threshold. The company itself has said nothing — the last official figure was 78 events. In the absence of confirmation, the rally is a wager on a rumor rather than a reaction to verified news, and that ambiguity is precisely what makes the stock so difficult to handicap.

The speculation has landed in a market environment already primed for oncology bets. Moderna's Phase 3 success with its mRNA cancer vaccine in melanoma patients has triggered a broad re-rating of cancer immunotherapy names and lifted risk appetite across biotech. Sellas is riding that wave even though its own study targets a different disease with a different mechanism. The sector tailwind is real, but it doesn't validate the specific claim about REGAL.

The Bull Case: Analyst Targets and a Cash Cushion

For those inclined to believe the rumor, the setup is genuinely compelling. Maxim maintains a Buy rating with a $30 price target, well above current levels. Alliance Global went further in mid-August, lifting its target from $25 to $35, while citing encouraging Moderna data as a positive signal for the upcoming Sellas readout. At least one independent analysis has sounded a cautionary note, however, arguing that recent financial results strengthen the balance-sheet and pipeline story without resolving the binary risk inherent in the REGAL decision.

That balance-sheet story is worth examining. Sellas ended the second quarter with $138.3 million in cash — a meaningful cushion that covers ongoing study costs, though hardly an unlimited reserve. The company also reported a widening net loss, a reminder that the burn rate remains a live concern. In the ongoing Phase 2 study of SLS009 in newly diagnosed first-line AML, 28 patients have been enrolled to date.

The pipeline itself offers additional optionality. SLS009 is being studied in combination with established oncology players, feeding partnership speculation that goes beyond the REGAL catalyst. If the 80-event threshold is officially confirmed and a positive overall survival signal follows in the fourth quarter, the path toward accelerated regulatory discussions for SLS009 in AML would be open.

The Bear Case: Thin Liquidity and Unverified Claims

The risks are equally concrete. The rally has been characterized in part as short-covering amplified by limited free-float liquidity — patterns typically associated with thin institutional support and elevated pullback potential. The company's management has had to publicly defend the study, a sign of skepticism in the market about the data quality.

The volatility metric tells its own story: annualized 30-day volatility stands at 98 percent. That's a measure of how violently the stock can move in either direction on any new piece of information. An official denial of the 80-event figure, or a delay of the overall survival data into next year, could erase recent gains as quickly as they appeared.

The stock's distance from its 52-week high of €15.25, reached on June 30, is roughly 20 percent. That gap reflects how much of the recent run-up has already been given back — and how fragile the current level may be if the narrative shifts.

Two Paths to the Fourth Quarter

The next concrete milestone is the fourth-quarter release of final overall survival data from REGAL. Until then, the stock is caught between hope and unconfirmed rumor, likely to remain volatile but supported as long as speculation dominates the news flow and the company offers no contradiction.

If Sellas officially confirms the 80 events and delivers a positive overall survival signal, the recent advance could prove to be merely the opening phase of a more fundamental re-rating. The combination of a confirmed threshold, a positive readout, and sector-wide enthusiasm for cancer immunotherapy could create a powerful momentum story.

If, however, the narrative breaks — an official correction of the event count, or a failure to confirm — the correction could be sharp, the kind typical of thinly traded, highly speculative biotech names. The 98 percent volatility figure is a warning as much as a description.

What makes this situation unusual is the degree to which the market has already priced in a favorable outcome. The 898 percent gain from the November low is not a reflection of fundamental value creation; it's a bet on a binary event that hasn't yet been resolved. The company's own silence on the 80-event figure is telling — in an environment where biotech management teams are typically eager to announce positive milestones, the absence of confirmation speaks volumes.

For now, the stock sits at €12.75, caught between a rumor that has driven it 639 percent higher over twelve months and a company that has yet to say whether the rumor is true. The fourth quarter will provide the answer. Until then, investors are betting on a number that exists only in the market's collective imagination — and hoping the company eventually makes it real.